Marrying unmissable insights from global renal experts, the 1^st Rare & Genetic Kidney Disease Drug Development Summit is uniquely positioned to provide you with transformative perspectives from identifying genetic drivers of rare kidney diseases to innovative trial design in small disease populations to accelerate progress of your genetic kidney disease pipeline.

Hear from industry heavyweights including Sanofi Genzyme, Alexion, AstraZeneca, Regulus Therapeutics, Chinook Therapeutics, Ionis Pharmaceuticals, Novartis, Otsuka Pharmaceutical Companies and many more to ignite your entry to the rare and genetic kidney disease landscape and confidently progress from proof of concept to the clinic.

Discover pivotal advances in disease modelling with stem cell-derived kidney organoids, explore opportunities for comprehensive genetic diagnosis and patient stratification, and join the conversation on progressing surrogate biomarkers and endpoints to guide strategic decisions on your pipeline in ADPKD, Alport Syndrome and more.

Get involved to understand why interest in rare and genetic kidney diseases is exploding and keep up to date with the latest opportunities for genetic intervention.

To know more visit: https://ter.li/k0fu1i